Beyond criticism for its slow deliveries, notably in Europe, AstraZeneca also has had to deal with reports of dangerous blood clots in some recipients of its shot, although the company and international regulators say there is no evidence the vaccine is to blame. Several countries, including Germany, France, Italy and Spain, have suspended its use.
The EU's drug regulator insisted Tuesday that there is no indication it does so, and von der Leyen said Wednesday that I trust AstraZeneca, I trust the vaccines.
AstraZeneca's formula is one of three vaccines in use on the continent. But the escalating concern is another setback for the EU's vaccination drive, which has been plagued by shortages and other hurdles and is lagging well behind the campaigns in Britain and the US.
For the second quarter of 2021, van der Leyen said, AstraZeneca will only deliver 70 million doses, less than half of the 180 million it was contractually obliged to deliver.
Two production sites in the UK figure in the EU's advance purchasing agreement drawn up with AstraZeneca, she said, adding: We're still waiting for doses to come from the UK," she said.
Von der Leyen also noted the EU has exported around 41 million vaccine doses to other countries. But open roads run in both directions, and this is why we need to ensure that there is reciprocity and proportionality, she said.
If the situation does not change, we will have to reflect on how to make exports to vaccine producing countries dependent on their level of openness, she added, without naming any country.
She said the EU still aims to vaccinate 70% of all adults by September.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.